DiaMedica Therapeutics Inc. (DMAC) NASDAQ
6.48
+0.06(+0.93%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
6.48
+0.06(+0.93%)
Currency In USD
Address
Two Carlson Parkway
Minneapolis, MN 55447
United States of America (the)
Phone
763 612 6755
Website
Sector
Healthcare
Industry
Biotechnology
Employees
27
First IPO Date
August 03, 2012
| Name | Title | Pay | Year Born |
| Dietrich John Pauls | President, Chief Executive Officer & Director | 917,475 | 1971 |
| Scott Kellen | Chief Financial Officer & Corporate Secretary | 539,434 | 1965 |
| Julie Krop | Chief Medical Officer | 562,053 | 1966 |
| Alex Aimetti | Chief Development Officer | 0 | N/A |
| Ambarish Shah | Chief Technology Officer | 0 | N/A |
| Dominic R. Cundari | Chief Commercial Officer | 0 | 1951 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.